StarOne IP Group v. Cardinal Health: 1-Day Patent Case Over Formalin Safety Containers
StarOne Intellectual Property Group Ltd. filed a patent infringement action against Cardinal Health, Inc. in the Southern District of Ohio, asserting US7475774B2 over Cardinal Health’s BiopSafe® Formalin Safety Container line. The case closed just one day after filing — an exceptionally compressed timeline that raises immediate questions about voluntary withdrawal or rapid settlement.
One-day infringement action in Ohio’s formalin container IP space
On 22 May 2024, StarOne Intellectual Property Group Ltd. filed case no. 1:24-cv-00296 in the Southern District of Ohio before Chief Judge Michael R. Barrett, asserting patent infringement against Cardinal Health, Inc. The single patent at issue is US7475774B2, and the accused products are Cardinal Health’s BiopSafe® Formalin Safety Container in 20ml (model 3178-20000) and 60ml (model 3178-60000) configurations — sealed specimen containment devices used in clinical pathology workflows.
The case closed on 23 May 2024 — just one day after filing. No basis of termination, verdict, or costs ruling has been recorded in the publicly available docket. The absence of any defendant law firm entry and the lack of a recorded verdict suggests the matter was resolved, withdrawn, or administratively closed before Cardinal Health was formally served or entered an appearance.
A one-day case duration is extraordinary even by the standards of quickly resolved patent disputes. Early resolution at this stage typically suggests a pre-filing settlement was reached and the complaint was filed and then promptly withdrawn, or that a procedural or jurisdictional defect prompted immediate voluntary dismissal. The public record is silent on which scenario applies, and the true terms — including any licensing arrangement — remain unknown.
Filing to dismissal in 1 days
Closed after just 1 day — among the shortest-lived patent filings on record
Case closed after one day — basis of termination not publicly recorded
Closed in 24 hours: what a one-day case typically signals
A patent case closing the day after filing almost never reflects a substantive judicial ruling. It most commonly indicates a voluntary dismissal filed by the plaintiff shortly after lodging the complaint — often because a settlement or licensing agreement was reached pre-filing, or because counsel identified a procedural issue requiring refiling. No adverse finding against either party should be inferred from this timeline alone.
Procedural early exitWith or without prejudice? The public record is silent
When a case closes this quickly, the critical legal question is whether dismissal was with or without prejudice. Dismissal with prejudice bars StarOne from refiling the same claims against Cardinal Health. Dismissal without prejudice leaves that option open. The docket as publicly available does not specify which applies here. Practitioners should monitor the docket directly to confirm the order’s terms before drawing conclusions about StarOne’s enforcement posture.
Prejudice status unconfirmedNo defence filing recorded — Cardinal Health may not have been formally served
The absence of any defendant law firm entry or defence agent on the docket is consistent with a case that resolved before service of process was completed or accepted. In federal patent practice, a defendant has 21 days to respond after service. If the case closed before that window, Cardinal Health may have had no formal obligation to respond — and the resolution, whatever its terms, was likely driven entirely by plaintiff-side action.
Pre-answer resolutionStarOne’s filing suggests active monetisation of US7475774B2
StarOne Intellectual Property Group Ltd. is structured as an IP holding entity, consistent with a patent monetisation strategy rather than product competition. Filing against Cardinal Health — a Fortune 50 healthcare distributor — over two specific SKUs of a formalin safety container suggests targeted, product-mapped enforcement. Whether this results in licensing revenue or further litigation against other market participants is a pattern worth monitoring.
NPE enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | StarOne Intellectual Property Group Ltd. | Company | IP holding group — holder of US7475774B2 covering formalin safety container technologySearch in Eureka ↗ |
| Defendant | Cardinal Health, Inc. | Company | Cardinal Health, Inc. — major U.S. healthcare products and distribution companySearch in Eureka ↗ |
| Plaintiff counsel | Meredith Rachel Lloyd | Attorney | Counsel for StarOne Intellectual Property Group Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Michael R. Barrett | Chief Judge | Ohio Southern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
No verdict was recorded in this case. The matter closed one day after filing without any substantive ruling on the merits of the infringement claim. This means there is no judicial determination — positive or negative — regarding the validity of US7475774B2 or Cardinal Health’s alleged infringement of it. The absence of a verdict should not be interpreted as a finding in favour of either party.
US7475774B2 — Formalin Safety Container Technology
US7475774B2 (application no. US10/570599) is a granted U.S. utility patent covering formalin safety container technology — a product category used in clinical and surgical pathology to safely transport and preserve biopsy specimens in formalin fixative. Formalin is a formaldehyde solution classed as a hazardous chemical, and containment designs must address leak prevention, vapour control, and user safety. The patent’s application number sequence suggests an early-to-mid 2000s priority date, placing it in a period of growing regulatory focus on hazardous chemical handling in clinical settings.
For the clinical pathology supply market, US7475774B2 represents a potentially blocking position on design features that have since become broadly adopted across formalin safety container products. Cardinal Health’s BiopSafe® line is among the most widely distributed such products in the U.S. market. If the patent’s claims are broad enough to read on standard container architectures, other distributors and private-label manufacturers selling comparable 20ml and 60ml containers may face similar exposure. The case’s rapid closure suggests the parties resolved the matter without judicial claim construction — leaving the patent’s enforceability untested.
Should your team run an FTO against US7475774B2?
Any company designing, manufacturing, or distributing formalin safety containers — including sealed biopsy specimen jars, pre-filled formalin kits, or pathology specimen transport systems — should treat US7475774B2 as a live risk. StarOne’s enforcement action against Cardinal Health’s BiopSafe® line demonstrates that the patent holder is actively monitoring the market. If your products share structural or functional features with the accused SKUs (20ml and 60ml sealed formalin containers), an FTO analysis is commercially prudent before your next product launch or SKU refresh.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to run a structured freedom-to-operate query against US7475774B2’s claim set — mapping your product’s features against the patent’s independent and dependent claims. Eureka can also flag related continuations, divisionals, or family members that may not yet be asserted but carry overlapping claim scope. Setting a claim monitoring alert on this patent ensures your team is notified of any prosecution history updates, reexamination filings, or new enforcement actions before they reach your product line.
Run a freedom-to-operate analysis on US7475774B2 to assess your product’s exposure
Run FTO in Eureka →Similar formalin container and medical device patent infringement cases
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the clinical specimen containment IP landscape
A one-day filing against a major healthcare distributor over a niche containment patent is a pattern that warrants attention across the pathology supply chain.
Formalin container designs are now active patent enforcement targets
US7475774B2 covers technology embedded in a product category — formalin safety containers — that most manufacturers treat as a commodity. StarOne’s decision to file against Cardinal Health’s BiopSafe® line signals that at least one IP holder views this space as commercially licensable. Competitors selling similar specimen container SKUs should treat this as an early indicator of broader enforcement activity.
One-day closures often conceal licensing outcomes — monitor StarOne’s next filing
When a case closes this quickly, the most commercially significant outcome — a licensing agreement — is typically invisible in the public record. If StarOne secured a licence from Cardinal Health, the next logical step is assertion against other distributors or manufacturers in the same product category. Tracking subsequent filings by StarOne or Bochner PLLC is the most reliable way to map the enforcement trajectory of this patent.
StarOne v Cardinal — key questions answered
StarOne Intellectual Property Group Ltd. filed a patent infringement action against Cardinal Health, Inc. in the Southern District of Ohio on 22 May 2024, asserting US7475774B2 over Cardinal Health’s BiopSafe® Formalin Safety Containers (20ml and 60ml). The case closed one day later on 23 May 2024 without a recorded verdict or stated basis of termination.
The public record does not specify the reason. A one-day closure most commonly indicates a voluntary dismissal by the plaintiff — often following a pre-filing settlement, licensing agreement, or identification of a procedural issue. No substantive hearing or ruling took place. The basis of termination and any financial terms are not publicly available from the docket.
US7475774B2 (application no. US10/570599) covers formalin safety container technology used in clinical pathology for the safe transport and preservation of biopsy specimens. Cardinal Health’s accused products are the BiopSafe® Formalin Safety Container in 20ml (model 3178-20000) and 60ml (model 3178-60000) configurations.
The publicly available docket does not record the basis of termination or specify whether any dismissal was with or without prejudice. Practitioners seeking a definitive answer should access the Southern District of Ohio PACER docket for case 1:24-cv-00296 to review any filed order or stipulation.
StarOne Intellectual Property Group Ltd. was represented by Bochner PLLC, with attorney Meredith Rachel Lloyd listed as plaintiff’s agent. No defendant law firm was recorded on the docket, consistent with the case closing before Cardinal Health formally appeared or was served.
PatSnap Eureka searches patents and litigation data to answer instantly.